Circulating tumor cells on the go with Biocept IPO
This article was originally published in Clinica
Another diagnostics company, Biocept Laboratories, is taking its chances on the public market. The San Diego, California company specializes in biomarker analysis and measurement of circulating tumor cells (CTCs), which could be used for the diagnosis, prognosis and monitoring of cancer. It is hoping to raise up to $23m, according to its filing with the US Securities and Exchange Commission (SEC) – but did not say how many shares it plans to sell or their price. Biocept will list on the Nasdaq market under the ticker symbol BIOC.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.